Glenmark launches Zita Plus Pio drug for Type 2 Diabetes in India

Glenmark Pharmaceuticals Limited (Glenmark), has launched a novel fixed-dose combination (FDC) of a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, with Pioglitazone. 
According to an official media release by the company, this is the only available DPP4 and Glitazone combination brand in India for adults with uncontrolled Type 2 diabetes. Glenmark has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) + Pioglitazone (15 mg), to be taken once a day.

Commenting on the development, Alok Malik, Group Vice President & Head, India Formulations – Glenmark Pharmaceuticals, said, “Diabetes is a key area of focus for Glenmark; a pioneer in providing access to the latest treatment options to diabetic patients in India. We are delighted to introduce this novel Zita Plus Pio, which is the first of its kind in India; offering a world-class and affordable treatment option to adult diabetic patients.”

Glenmark is the first company in India to market the FDC of Teneligliptin + Pioglitazone, which is approved by the DCGI (Drug Controller General of India). This fixed dose combination will be useful for patients who require treatment with Teneliglitptin and Pioglitazone (as separate drugs) to improve glycemic control reducing Insulin Resistance.  

Type 2 diabetics typically face issues of β cell dysfunction and insulin resistance. Glenmark’s FDC of Teneligliptin + Pioglitazone has the efficacy to tackle these two most important pathophysiologies which makes the FDC more effective in managing uncontrolled Type 2 diabetes. The combination of Teneligliptin + Pioglitazone will provide a synergistic approach wherein Teneligliptin will optimally improve β cell sensitivity, and Pioglitazone will effectively reduce insulin resistance.